Portfolio company
Adicet Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Adicet Bio develops allogeneic gamma delta T cell therapies for patients with autoimmune diseases and cancer.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ACET
Adicet Bio develops allogeneic gamma delta T cell therapies for patients with autoimmune diseases and cancer.
Allogene Therapeutics
The company develops off-the-shelf allogeneic CAR T-cell therapies for patients with blood cancers, solid tumours and autoimmune diseases.
Artiva Biotherapeutics
The company develops allogeneic natural killer cell therapies for patients with autoimmune diseases and cancer.
LAVA Therapeutics
The company develops bispecific antibodies that engage gamma-delta T cells to treat hematological and solid cancers.
GentiBio
GentiBio develops engineered regulatory T cell therapies to restore immune tolerance for patients with autoimmune, alloimmune, autoinflammatory and allergic diseases.
Orca Bio
This company develops high-precision allogeneic cell therapies to treat patients with blood cancers and autoimmune diseases by replacing diseased immune systems with donor cells.
Appia Bio
This company develops engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.